MedDataX Logo

Rate Control in Atrial Fibrillation

NCT ID: NCT01655303

Last Updated: 2012-08-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rate control in atrial fibrillation is a usual battle in emergency departments. Oral medications have a natural superiority to intravenous ones because they are easy-to-use and decrease the workload in busy emergency departments.

This study wants to find an effective oral medication for rate control in rapid ventricular response atrial fibrillation. Propranolol and Metoprolol, Diltiazem and Verapamil are compared in patients with a stable hemodynamic status.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rapid Ventricular Response Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metoprolol Per Oral

50 mg Metoprolol

Group Type EXPERIMENTAL

Metoprolol

Intervention Type DRUG

Verapamil

40 mg Verapamil Per Oral

Group Type EXPERIMENTAL

Verapamil

Intervention Type DRUG

Propranolol

40 mg Propranolol Per Oral

Group Type EXPERIMENTAL

Propranolol

Intervention Type DRUG

Diltiazem

60 mg Diltiazem Per Oral

Group Type EXPERIMENTAL

Diltiazem

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propranolol

Intervention Type DRUG

Metoprolol

Intervention Type DRUG

Verapamil

Intervention Type DRUG

Diltiazem

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inderal Metoral

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age more than 18 years old
* Stability in hemodynamic

Exclusion Criteria

* Systolic blood pressure less than 90 mm Hg
* Altered mental status attributable to rapid ventricular response atrial fibrillation
* Acute pulmonary edema attributable to rapid ventricular response atrial fibrillation
* Chest pain attributable to rapid ventricular response atrial fibrillation
* Allergy to Propranolol or Metoprolol or Verapamil or Diltiazem
* History of asthma
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tehran University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rasoul-e-Akram Hospital

Tehran, Tehran Province, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16057

Identifier Type: -

Identifier Source: org_study_id